165 related articles for article (PubMed ID: 24051255)
1. Intermittent single-agent doxorubicin for the treatment of canine B-cell lymphoma.
Higginbotham ML; McCaw DL; Roush JK; Nietfeld JC; Wilkerson MJ; Reeds K; Burr D
J Am Anim Hosp Assoc; 2013; 49(6):357-62. PubMed ID: 24051255
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
Simon D; Moreno SN; Hirschberger J; Moritz A; Kohn B; Neumann S; Jurina K; Scharvogel S; Schwedes C; Reinacher M; Beyerbach M; Nolte I
J Am Vet Med Assoc; 2008 Mar; 232(6):879-85. PubMed ID: 18341445
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma.
Al-Nadaf S; Rebhun RB; Curran KM; Venable RO; Skorupski KA; Willcox JL; Burton JH
BMC Vet Res; 2018 Nov; 14(1):356. PubMed ID: 30458771
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.
Davies O; Szladovits B; Polton G; Garden OA; Leo C; Lara-Garcia A
Vet Comp Oncol; 2018 Jun; 16(2):276-287. PubMed ID: 29271043
[TBL] [Abstract][Full Text] [Related]
5. Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma.
Elliott JW; Cripps P; Marrington AM; Grant IA; Blackwood L
Vet Comp Oncol; 2013 Sep; 11(3):185-98. PubMed ID: 22372620
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma.
Khanna C; Lund EM; Redic KA; Hayden DW; Bell FW; Goulland EL; Klausner JS
J Am Vet Med Assoc; 1998 Oct; 213(7):985-90. PubMed ID: 9776993
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cytoreductive efficacy of vincristine, cyclophosphamide, and Doxorubicin in dogs with lymphoma by measuring the number of neoplastic lymphoid cells with real-time polymerase chain reaction.
Sato M; Yamazaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
J Vet Intern Med; 2011; 25(2):285-91. PubMed ID: 21314729
[TBL] [Abstract][Full Text] [Related]
11. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
[TBL] [Abstract][Full Text] [Related]
12. Treatment of canine lymphoma with COPLA/LVP.
Boyce KL; Kitchell BE
J Am Anim Hosp Assoc; 2000; 36(5):395-403. PubMed ID: 10997514
[TBL] [Abstract][Full Text] [Related]
13. Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008).
Beaver LM; Strottner G; Klein MK
J Am Vet Med Assoc; 2010 Nov; 237(9):1052-5. PubMed ID: 21034344
[TBL] [Abstract][Full Text] [Related]
14. Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?
Marconato L; Bonfanti U; Stefanello D; Lorenzo MR; Romanelli G; Comazzi S; Zini E
Vet Comp Oncol; 2008 Jun; 6(2):80-9. PubMed ID: 19178667
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma.
Sorenmo KU; Baez JL; Clifford CA; Mauldin E; Overley B; Skorupski K; Bachman R; Samluk M; Shofer F
J Vet Intern Med; 2004; 18(2):209-13. PubMed ID: 15058772
[TBL] [Abstract][Full Text] [Related]
16. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.
Rebhun RB; Kent MS; Borrofka SA; Frazier S; Skorupski K; Rodriguez CO
Vet Comp Oncol; 2011 Mar; 9(1):38-44. PubMed ID: 21303452
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
Vail DM; Chun R; Thamm DH; Garrett LD; Cooley AJ; Obradovich JE
Clin Cancer Res; 1998 Jun; 4(6):1567-71. PubMed ID: 9626479
[TBL] [Abstract][Full Text] [Related]
18. Increase in minimal residual disease in peripheral blood before clinical relapse in dogs with lymphoma that achieved complete remission after chemotherapy.
Sato M; Yamazaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
J Vet Intern Med; 2011; 25(2):292-6. PubMed ID: 21314721
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma.
Keller ET; MacEwen EG; Rosenthal RC; Helfand SC; Fox LE
J Vet Intern Med; 1993; 7(5):289-95. PubMed ID: 8263847
[TBL] [Abstract][Full Text] [Related]
20. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival.
Valli VE; Kass PH; San Myint M; Scott F
Vet Pathol; 2013 Sep; 50(5):738-48. PubMed ID: 23444036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]